Kadiyala Deepak, Roer David A, Perazella Mark A
St Mary's Hospital, Waterbury, CT, USA.
Am J Kidney Dis. 2009 Jan;53(1):133-7. doi: 10.1053/j.ajkd.2008.09.016. Epub 2008 Nov 20.
Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder of patients with kidney disease that is associated with gadolinium-based contrast exposure. Most cases are linked to gadodiamide. Gadoversetamide, an agent with chelate characteristics similar to gadodiamide, has rarely been described to cause NSF. With the exception of normalization of kidney function, there are no consistently effective therapies for patients with NSF. We describe 3 cases of NSF in patients with end-stage renal disease after gadolinium-based contrast exposure. Two patients received gadoversetamide and the third received gadodiamide. All 3 patients were treated early in their disease course with intravenous sodium thiosulfate and responded with improved skin changes and joint mobility.
肾源性系统性纤维化（NSF）是一种折磨肾病患者的纤维化疾病，与接触钆基造影剂有关。大多数病例与钆双胺有关。钆布醇是一种螯合特性与钆双胺相似的药物，很少被描述会导致NSF。除肾功能恢复正常外，对于NSF患者没有始终有效的治疗方法。我们描述了3例终末期肾病患者在接触钆基造影剂后发生NSF的病例。2例患者接受了钆布醇，第3例接受了钆双胺。所有3例患者在病程早期均接受了静脉注射硫代硫酸钠治疗，皮肤变化和关节活动度均有所改善。
